Cover Image
Market Research Report
Product code 
1069392

Moderate to Severe TBIs - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report

Published: | GervanoRA Data Services LLP | 175 Pages | Delivery time: 3-5 business days

Price

Back to Top
Moderate to Severe TBIs - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
Published: January 25, 2022
GervanoRA Data Services LLP
Content info: 175 Pages
Delivery time: 3-5 business days
  • Description
  • Table of Contents
  • List of Tables

GervanoRA's pipeline analysis and opportunity assessment report, "Moderate to Severe TBIs - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022" analysed and assessed Moderate to Severe TBIs pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Moderate to Severe TBIs drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Moderate to Severe TBIs area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Moderate to Severe TBIs drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Moderate to Severe TBIs historical and forecasted epidemiology based market trends Worldwide, the United States, EU8 (Poland, Spain, Switzerland, Sweden, Italy, Germany, Austria, France), United Kingdom and China. A detailed analytics on the Current Moderate to Severe TBIs Market (2021) and the Forecasted Moderate to Severe TBIs Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Moderate to Severe TBIs Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Moderate to Severe TBIs Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Moderate to Severe TBIs Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

Product Code: GERPH212213

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MODERATE TO SEVERE TBIS OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: MODERATE TO SEVERE TBIS CURRENT MARKET VALUE AND FORECAST 2021 - 2030

CHAPTER 5: COMPARATIVE PIPELINE INSIGHTS AND BENCHMARKING SNAPSHOTS

CHAPTER 6: DEALS ACTIVITIES OF MODERATE TO SEVERE TBIS COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF MODERATE TO SEVERE TBIS PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

CHAPTER 10: MARKET DYNAMICS

CHAPTER 11: COMPETITOR NEW DRUGS PRICING STRATEGIES

LIST OF TABLES

(COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: WORLDWIDE EPIDEMIOLOGY INSIGHTS OF MODERATE TO SEVERE TBIS
  • TABLE 03: GLOBAL MODERATE TO SEVERE TBIS EPIDEMIOLOGY (2020), FORECAST (2021-2030)
  • TABLE 04: US MODERATE TO SEVERE TBIS EPIDEMIOLOGY (2020), FORECAST (2021-2030)
  • TABLE 05: UK MODERATE TO SEVERE TBIS EPIDEMIOLOGY (2020), FORECAST (2021-2030)
  • TABLE 06: LIST OF NEW ENTRANTS CONSIDERED FOR MARKET ESTIMATIONS
  • TABLE 07: MODERATE TO SEVERE TBIS GLOBAL CURRENT MARKET (2020), FORECAST (2021-2030)
  • TABLE 08: MODERATE TO SEVERE TBIS US CURRENT MARKET (2020), FORECAST (2021-2030)
  • TABLE 09: COMPARISON OF MODERATE TO SEVERE TBIS MARKET VALUES GLOBAL VERSUS US (2020-2030)(M$)
  • TABLE 10: PIPELINE ASSETS IN MODERATE TO SEVERE TBIS DRUG PIPELINE
  • TABLE 11: SPECIAL REGULATORY ALLOWANCES GRANTED FOR MODERATE TO SEVERE TBIS PIPELINE DRUGS
  • TABLE 12: MODERATE TO SEVERE TBIS PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
  • TABLE 13: MODERATE TO SEVERE TBIS PIPELINE ANALYTICS BY DRUG CLASS
  • TABLE 14: MODERATE TO SEVERE TBIS PIPELINE ANALYTICS BY MECHANISM OF ACTION
  • TABLE 15: MODERATE TO SEVERE TBIS PIPELINE ANALYTICS BY MOLECULE TYPE
  • TABLE 16: MAJOR MERGERS AND ACQUISITIONS IN MODERATE TO SEVERE TBIS THERAPEUTIC AREA
  • TABLE 17: MAJOR COLLABORATION AGREEMENTS IN MODERATE TO SEVERE TBIS THERAPEUTIC AREA
  • TABLE 18: MAJOR LICENSING AGREEMENTS IN MODERATE TO SEVERE TBIS THERAPEUTIC AREA
  • TABLE 19: MAJOR FINANCING AGREEMENTS IN MODERATE TO SEVERE TBIS THERAPEUTIC AREA
  • TABLE 20: MAJOR TERMINATION AND SETTLEMENT AGREEMENTS IN MODERATE TO SEVERE TBIS THERAPEUTIC AREA
  • TABLE 21: COMPANIES LOOKING FOR CORPORATE PARTNERING, LICENSING, FUNDING OPPORTUNITIES
  • TABLE 22: ESTIMATED R&D INVESTMENTS OF NEW ENTRANTS

LIST OF FIGURES

(COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: MODERATE TO SEVERE TBIS FORECASTED PREVALENCE & INCIDENCE OF US, EUROPE AND CHINA, 2020 V/S 2030
  • FIGURE 02: GLOBAL MODERATE TO SEVERE TBIS POPULATION (2020) FORECAST (2021-2030)
  • FIGURE 03: US MODERATE TO SEVERE TBIS POPULATION (2020) FORECAST (2021-2030)
  • FIGURE 04: GLOBAL MODERATE TO SEVERE TBIS MARKET CURRENT (2020) AND FORECAST (2021-2030)
  • FIGURE 05: US CURRENT (2020) MODERATE TO SEVERE TBIS MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
  • FIGURE 06: YEAR BY YEAR COMPARISON OF MODERATE TO SEVERE TBIS MARKET VALUES GLOBAL VS USA (2020 - 2030) (M$)
  • FIGURE 07: MODERATE TO SEVERE TBIS PIPELINE DRUGS ANALYTICS
  • FIGURE 08: MODERATE TO SEVERE TBIS PIPELINE DRUGS ANALYTICS BY HSD
  • FIGURE 09: MODERATE TO SEVERE TBIS PIPELINE ANALYTICS BY ROA
  • FIGURE 10: MODERATE TO SEVERE TBIS PIPELINE ANALYTICS BY DRUG CLASS
  • FIGURE 11: MODERATE TO SEVERE TBIS PIPELINE ANALYTICS BY DRUG CLASS VERSUS HSD
  • FIGURE 12: MODERATE TO SEVERE TBIS PIPELINE ANALYTICS BY MECHANISM OF ACTION
  • FIGURE 13: MODERATE TO SEVERE TBIS PIPELINE ANALYTICS BY MOLECULE TYPE
  • FIGURE 14: MODERATE TO SEVERE TBIS PIPELINE ANALYTICS BY COMPANY TYPE
  • FIGURE 15: MODERATE TO SEVERE TBIS DEALS ANALYTICS BY DEAL TYPE